Co-Diagnostics, Inc.

Stage 4 · Declining · week 11

As of Oct 22, 2026, Co-Diagnostics is in Stage 4, the downtrend phase, now in week 11 (since Aug 6, 2026). It closed at $0.57, 98.5% below its 52-week high and below its 200-day average, which is falling.

$0.57

-12.31% today

$4.0M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CODX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S2 14w

S4 40w

S4 20w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 6w → S4 9w → S1 6w → S2 5w → S3 5w → S4 12w → S1 1w → S2 14w → S3 3w → S2 3w → S3 2w → S4 40w → S1 10w → S2 4w → S3 5w → S4 20w → S1 10w → S4 11w current

Total tracked: 166 weeks across 18 stage runs.

CODX among Medical Devices123rd of 141 by relative strength

All 141 →

Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	TXG10x Genomics, Inc.	Stage 2 · wk 48	99	−7.8%
2	RCELAvita Medical, Inc.	Stage 2 · wk 13	98	+40.8%
3	BFLYButterfly Network, Inc. Class A	Stage 2 · wk 26	98	−26.0%
4	HAEHaemonetics Corporation	Stage 2 · wk 17	96	+8.7%
5	GKOSGlaukos Corporation	Stage 2 · wk 25	96	+15.1%
6	AXGNAxogen, Inc.	Stage 3 · wk 2	95	−15.3%
7	NEOGNeogen Corporation	Stage 2 · wk 14	95	−11.7%
8	BVSBioventus Inc. Class A	Stage 2 · wk 15	95	+10.5%
…123	CODXCo-Diagnostics, Inc.	Stage 4 · wk 11	5	−48.2%

vs 52W High

-98.5%

$0.57 lo$37.80 hi

98.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 11

1w13w26w

Week 11, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-75.6%

200 DMA: $2.34 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.51x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-48.2%

-72.9%

-66.7%

YTD

-89.7%

-94.4%

Scan Membership

Breakout Watch

Latest: 2024-10-14

5 appearances in last 60 days. First seen: 2019-09-19.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 11 · Vol 1.51x

2026-10-21S4

Wk 11 · Vol 2.10x

2026-10-20S4

Wk 11 · Vol 1.75x

2026-10-19S4

Wk 11 · Vol 0.20x

2026-10-16S4

Wk 11 · Vol 0.96x

2026-10-15S4

Wk 10 · Vol 0.81x

2026-10-14S4

Wk 10 · Vol 3.11x

2026-10-13S4

Wk 10 · Vol 1.56x

2026-10-12S4

Wk 10 · Vol 2.04x

2026-10-09S4

Wk 10 · Vol 0.33x

2026-10-08S4

Wk 9 · Vol 0.41x

2026-10-07S4

Wk 9 · Vol 0.49x

Moving averages & range

50 DMA

$1.08

200 DMA

$2.34

52W High

$37.80

52W Low

$0.57

5D Low

$0.57

Resistance levels (recent highs)

20d High

$1.25

60d High

$1.56

120d High

$11.19

250d High

$37.80

Next resistance

+119.3%

to 20d High

ROE

-174.8%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.2

Co-Diagnostics: quick answers

What stage is Co-Diagnostics in?

As of Oct 22, 2026, Co-Diagnostics (CODX) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 6, 2026 and is in week 11. What the four stages mean

Is Co-Diagnostics in an uptrend?

No. Co-Diagnostics is in a Stage 4 downtrend. It trades 75.6% below its 200-day average, which is falling.

How far is Co-Diagnostics from its 52-week high?

Co-Diagnostics closed at $0.57 on Oct 22, 2026, 98.5% below its 52-week high of $37.80. Its 52-week low is $0.57.

How has Co-Diagnostics performed over the past year?

As of Oct 22, 2026, Co-Diagnostics is down 94.4% over the past year and down 89.7% so far in 2026.

Which sector and industry is Co-Diagnostics in?

Co-Diagnostics is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.